Catalyst Capital Advisors’s Medifast MED Stock Holding History

Catalyst Capital Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,000	Closed	-$444K	–	534
2017 Q1	$444K	Buy	+10,000	New	+$430K	0.02%	220
2016 Q3	–	Sell	-28,100	Closed	-$935K	–	491
2016 Q2	$935K	Buy	28,100 +4,800	+21%	+$155K	0.17%	141
2016 Q1	$703K	Buy	+23,300	New	+$681K	0.12%	135

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Catalyst Capital Advisors's MED Position: Q2 2017 in Review

Catalyst Capital Advisors sold out of Medifast (MED) in Q2 2017, closing a stake of 10,000 shares — an estimated $444K sold.

Catalyst Capital Advisors first reported a position in MED in Q1 2016 and held it in 3 quarters. The position peaked at $935K in Q2 2016. 161 funds tracked by Wall St. Rank hold MED as of Q2 2017.

Catalyst Capital Advisors reported no remaining Medifast position as of Q2 2017 after selling out during the quarter.
Catalyst Capital Advisors sold 10,000 Medifast shares in Q2 2017, an estimated $444K.
Catalyst Capital Advisors first reported a position in Medifast in Q1 2016 and held it in 3 quarters.
Catalyst Capital Advisors's Medifast position peaked at $935K in Q2 2016.
161 funds tracked by Wall St. Rank held Medifast as of Q2 2017.

Based on Catalyst Capital Advisors's 13F filing for Q2 2017, filed 2 Aug 2017.